Polycystic ovary syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: group number 1 (25 patient) metformin 500 mg three times a day (first week 500 mg daily then second week 500 mg two times a day and third week 500 mg three times a day and continuous w
Treatment - Drugs
group number 1 (25 patient) metformin 500 mg three times a day (first week 500 mg daily then second week 500 mg two times a day and third week 500 mg three times a day and continuous with 500 mg three
group number 2 (25 patient ) tab pioglitazone 30 mg daily for three month
group number3 (25 patient) tab metformin 500 mg three times a day (first week 500 mg daily then second week 500 mg two times a day and third week 500 mg three times a day and continuous with 500 mg th
Sponsors
Shahid Sadoughi University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age between 18 to 40 years old; diagnosed PCOS by AES (Androgen excess soiciety2006) criteria include: 1. Oligo or anovulation 2. Clinical or biochemical hyperandrogenism and rejection any other reasen cause to hyperandrogenism. Exclusion criteria: pregnancy and lactation; impaired liver and renal function tests; thyroid disorder; hyperprolactinemia; adrenal disorders; patient on estrogen and progesterone pills; the presence of type 1 and type 2 diabetes mellitus; late-onset congenital adrenal hyperplasia, and Cushing’s syndrome; none of the women had been taking clomiphene citrate, oral contraceptives, antiandrogens, insulin, minoxidil, phenytoin, cyclosporine, or drugs to control their appetite, lipid profile, during the previous 3 months and any severe systemic disease.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum Insulin level. Timepoint: before intervention and after intervention( after three month). Method of measurement: mili IU per liter.;Low density lipoprotein. Timepoint: before intervention and after intervention( after three month). Method of measurement: mili gram per deciliter.;High density lipoprotein. Timepoint: before intervention and after intervention( after three month). Method of measurement: mili gram per deciliter.;Triglyceride. Timepoint: before intervention and after intervention( after three month). Method of measurement: mililgram per deciliter.;Fast blood suger. Timepoint: before intervention and after intervention ( after three month). Method of measurement: milligram per deciliter.;Dehydroepiandrosterone sulphate. Timepoint: before intervention and after intervention( after three month). Method of measurement: milligram per liter.;17hydroxyprogestrone. Timepoint: before intervention and after intervention( after three month). Method of measurement: microgram per liter.;Total Testosterone. Timepoint: before intervention and after intervention( after three month). Method of measurement: microgram per liter.;LH/FSH ratio. Timepoint: before intervention and after intervention( after three month). Method of measurement: IU per liter.;Cholesterol. Timepoint: before intervention and after intervention( after three month). Method of measurement: milligram per deciliter. | — |
Secondary
| Measure | Time frame |
|---|---|
| Waist to hip ratio. Timepoint: before intervention and after intervention after three month. Method of measurement: meter.;Body Mass Index. Timepoint: before intervention and after intervention after three month. Method of measurement: kilogram per square meter.;Side effect of dugs. Timepoint: afer intervention (after three month). Method of measurement: descriptive.;Homeostatic Model Assessment-Insulin Resistance) HOMA -IR). Timepoint: before intervention and after intervention( after three month). Method of measurement: milli IU per deciliter /milli gram per deciliter. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Seyed Mojtaba Sohrevardi
Faculty of Pharmacy- Shahid Sadoughi University of Medical Sciences
Outcome results
None listed